{"product_id":"glpg-business-model-canvas","title":"Galapagos Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas: \u003cstrong\u003e3-5\u003c\/strong\u003e Page Strategic Blueprint with Word \u0026amp; Excel Templates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Galapagos’s business model with our concise Business Model Canvas—three to five pages of clear, actionable insights. Discover how Galapagos creates value, scales partnerships, and monetizes innovation. Download the complete Word and Excel files to benchmark, plan, or pitch with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma co-development alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartner with large pharma for late-stage development, regulatory strategy and global commercialization scale, leveraging partners with established regulatory teams and market access. These alliances de-risk pivotal trials and share costs—Phase III studies often exceed $100M—while accelerating time-to-market by up to 12–18 months. Joint steering committees align on milestones and indication prioritization. Co-promotion and profit-share structures expand geographic reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and research institutes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSince its 1999 founding, Galapagos collaborates with universities and translational centers and—through its strategic alliance with Gilead established in 2019—accesses novel target biology and patient samples. Academic KOLs validate mechanisms and refine trial endpoints. Sponsored research delivers first-in-class insights in inflammatory and fibrotic pathways, while consortia memberships boost credibility and data sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial networks and CROs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGalapagos leverages specialized CROs and multi-country site networks to run trials efficiently, tapping a CRO market \u0026gt;50 billion USD (2024) for capacity. Standardized protocols, centralized EDC and biomarker labs boost data quality and speed. Strategic site selection can raise enrollment rates ~25% in niche indications, while adaptive designs cut sample size\/time by up to 30%, lowering development risk and cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech platform and technology vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngage platform providers for target discovery, omics, AI\/ML and high-throughput screening to accelerate hit-to-lead and improve candidate selection. Licensed tools shorten timelines and reduce attrition, with AI-enabled discovery partners reporting measurable productivity gains. Cloud vendors (AWS, Azure, GCP \u0026gt;60% global market share in 2024) and companion diagnostic partners ensure secure, compliant analytics and patient stratification.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget discovery \u0026amp; omics platforms\u003c\/li\u003e\n\u003cli\u003eLicensed AI\/HTS tools for faster hit-to-lead\u003c\/li\u003e\n\u003cli\u003eCompanion diagnostics for stratification\u003c\/li\u003e\n\u003cli\u003eCloud\/data vendors for secure, compliant analytics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGalapagos partners with CDMOs for GMP drug substance and product manufacturing, covering complex biologics and small molecules; as of 2024 these external ties support scale-up and regulatory compliance.\u003c\/p\u003e\n\u003cp\u003eSupply-chain partners secure raw materials and cold-chain logistics to protect biologic integrity and reduce spoilage risk.\u003c\/p\u003e\n\u003cp\u003eTechnology transfer, process validation and dual-sourcing mitigate shortages and geographic disruption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDMO partnerships\u003c\/li\u003e\n\u003cli\u003eGMP \u0026amp; process validation\u003c\/li\u003e\n\u003cli\u003eCold-chain logistics\u003c\/li\u003e\n\u003cli\u003eDual-sourcing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner with big pharma, CROs and cloud AI to accelerate Phase III and global launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartner with large pharma (Gilead alliance 2019) for late-stage dev, regulatory strategy and global commercialization; Phase III often \u0026gt;100M USD and co-promotion speeds launch.\u003c\/p\u003e\n\u003cp\u003eAcademic KOLs, CROs (global CRO market \u0026gt;50B USD in 2024) and CDMOs provide translational validation, trial execution and GMP scale-up.\u003c\/p\u003e\n\u003cp\u003eAI\/omics and cloud vendors (AWS\/Azure\/GCP \u0026gt;60% market share in 2024) enable discovery, analytics and companion diagnostics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge pharma\u003c\/td\u003e\n\u003ctd\u003eCo-dev\/commercial\u003c\/td\u003e\n\u003ctd\u003ePhase III \u0026gt;100M USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrial delivery\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50B USD market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud\u003c\/td\u003e\n\u003ctd\u003eAnalytics\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% market share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Galapagos Business Model Canvas that maps customer segments, channels, value propositions and the full 9 BMC blocks with real-world operations and strategic insights; includes competitive-advantage analysis and linked SWOT to support validation, presentations, investor discussions and informed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Galapagos' strategy into a clean, editable one-page canvas that saves hours of setup, enables quick comparison across pipelines, and streamlines team collaboration for faster, board-ready decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTarget discovery and validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUse proprietary discovery platforms to identify novel targets in inflammation and fibrosis, integrating multi-omic datasets and high-content chemistry-enabled screening. Apply genetic, functional, and phenotypic screening cascades to prioritize candidates with disease-relevant biology. Validate mechanisms with preclinical models and translational biomarkers to de-risk translation. Build a robust pipeline funnel to accelerate clinical progression.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreclinical and translational research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOptimize leads for potency, selectivity and safety through iterative medicinal chemistry and in vitro assays, proceeding to GLP toxicology in two species and IND-enabling PK\/PD studies. GLP toxicology and CMC packages plus translational biomarker validation link biology to predicted clinical outcomes. Regulatory dossiers are compiled for FDA IND submission, which triggers the 30-day review clock.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign and run Phase 1–3 trials using rigorous protocols and adaptive designs to accelerate readouts and control costs. Manage patient recruitment and site operations for cohorts ranging from 50 (Phase 1) to 500–3,000 (Phase 3), with centralized monitoring to protect data integrity. Engage independent DSMBs, ensure GCP compliance across all sites, and generate pivotal evidence for FDA and EMA regulatory submissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEngage EMA and FDA for guidance, designations and approvals, leveraging FDA priority review (6 months) or standard review (10 months) and EMA accelerated assessment (150 days) where eligible; pursue breakthrough\/SRA designations to shorten timelines. Develop robust value dossiers and HEOR to support pricing and reimbursement and align clinical evidence to payer and HTA requirements.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory engagement: EMA, FDA; timelines 150d\/6m\/10m\u003c\/li\u003e\n\u003cli\u003eExpedited pathways: breakthrough, priority, accelerated\u003c\/li\u003e\n\u003cli\u003eMarket access: value dossiers, HEOR\u003c\/li\u003e\n\u003cli\u003eAlign evidence to payer\/HTA demands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and lifecycle management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePlan launches in prioritized geographies (US, EU, Japan) with targeted field teams; educate HCPs and patient communities to drive adoption; monitor real-world evidence as of 2024 to refine positioning and labels; explore line extensions, combinations and new indications to extend lifecycle and value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunch focus: US, EU, Japan\u003c\/li\u003e\n\u003cli\u003eHCP \u0026amp; patient education\u003c\/li\u003e\n\u003cli\u003e2024 RWE monitoring\u003c\/li\u003e\n\u003cli\u003eLine extensions \u0026amp; new indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-omic to market: discovery to Phase 3, FDA\/EMA engagement, \u003cstrong\u003e2024\u003c\/strong\u003e RWE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUse proprietary multi-omic discovery and chemistry-enabled screens with genetic\/phenotypic cascades to nominate targets and validate via translational biomarkers. Optimize leads via iterative medicinal chemistry, in vitro assays, GLP toxicology in two species and IND-enabling PK\/PD. Run Phase 1–3 trials (cohorts ~50 to 500–3,000), engage FDA\/EMA (FDA 6m\/10m, EMA 150d) and plan launches in US\/EU\/Japan with 2024 RWE monitoring.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscovery\u003c\/td\u003e\n\u003ctd\u003emulti-omic, high-content chemistry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eGLP tox: two species; IND PK\/PD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003ePhase sizes: ~50; 500–3,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/Launch\u003c\/td\u003e\n\u003ctd\u003eFDA 6m\/10m; EMA 150d; US\/EU\/Japan; 2024 RWE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Galapagos Business Model Canvas you’re previewing is the exact deliverable, not a mockup or sample, and shows real content from the final file. After purchase you’ll receive this same document in full, ready-to-edit and formatted for immediate use in Word and Excel. No hidden pages or placeholders—what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161414218105,"sku":"glpg-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/glpg-business-model-canvas.png?v=1762692435","url":"https:\/\/portersfiveforce.com\/products\/glpg-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}